E. U. Cabi Et Al. , "PEDMARK® REDUCED THE RISK OF CISPLATIN-INDUCED OTOTOXICITY IN PEDIATRIC PATIENTS WITH HEPATOBLASTOMA, SEEN IN A TURKISH COMPASSIONATE USE TREATMENT PROTOCOL," PEDIATRIC BLOOD & CANCER , 2023
Cabi, E. U. Et Al. 2023. PEDMARK® REDUCED THE RISK OF CISPLATIN-INDUCED OTOTOXICITY IN PEDIATRIC PATIENTS WITH HEPATOBLASTOMA, SEEN IN A TURKISH COMPASSIONATE USE TREATMENT PROTOCOL. PEDIATRIC BLOOD & CANCER .
Cabi, E. U., TAÇYILDIZ, N., ATASEVEN, E., Sivrice, A. C., SEVİNİR, B. B., Brock, P., ... Bhattacharya, A.(2023). PEDMARK® REDUCED THE RISK OF CISPLATIN-INDUCED OTOTOXICITY IN PEDIATRIC PATIENTS WITH HEPATOBLASTOMA, SEEN IN A TURKISH COMPASSIONATE USE TREATMENT PROTOCOL. PEDIATRIC BLOOD & CANCER .
Cabi, Emel Et Al. "PEDMARK® REDUCED THE RISK OF CISPLATIN-INDUCED OTOTOXICITY IN PEDIATRIC PATIENTS WITH HEPATOBLASTOMA, SEEN IN A TURKISH COMPASSIONATE USE TREATMENT PROTOCOL," PEDIATRIC BLOOD & CANCER , 2023
Cabi, Emel U. Et Al. "PEDMARK® REDUCED THE RISK OF CISPLATIN-INDUCED OTOTOXICITY IN PEDIATRIC PATIENTS WITH HEPATOBLASTOMA, SEEN IN A TURKISH COMPASSIONATE USE TREATMENT PROTOCOL." PEDIATRIC BLOOD & CANCER , 2023
Cabi, E. U. Et Al. (2023) . "PEDMARK® REDUCED THE RISK OF CISPLATIN-INDUCED OTOTOXICITY IN PEDIATRIC PATIENTS WITH HEPATOBLASTOMA, SEEN IN A TURKISH COMPASSIONATE USE TREATMENT PROTOCOL." PEDIATRIC BLOOD & CANCER .
@article{article, author={Emel Unal Cabi Et Al. }, title={PEDMARK® REDUCED THE RISK OF CISPLATIN-INDUCED OTOTOXICITY IN PEDIATRIC PATIENTS WITH HEPATOBLASTOMA, SEEN IN A TURKISH COMPASSIONATE USE TREATMENT PROTOCOL}, journal={PEDIATRIC BLOOD & CANCER}, year=2023}